Physician profile
Timothy Stephens
NPI 1578270831
$1,079.37
in general payments reported to CMS, 2019-2025
14 companies · $30.11 in 2025
The $30.11 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $595 · 2024: $455 · 2025: $30.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,079.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $270.37 | 2023-2024 | |
| Braeburn INC. | $198.98 | 2024 | Brixadi |
| Xeris Pharmaceuticals, INC. | $195.01 | 2023 | Gvoke Hypopen |
| Lilly USA, LLC | $110.59 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Alkermes, INC. | $77.34 | 2023-2024 | Vivitrol, Vivitrol |
| Novo Nordisk INC | $46.19 | 2023-2024 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $41.51 | 2023 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $30.06 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.03 | 2024 | Caplyta |
| Gilead Sciences, INC. | $17.52 | 2023 | Epclusa |
| Indivior INC. | $17.24 | 2024 | Sublocade |
| Phathom Pharmaceuticals, INC. | $16.99 | 2024 | Voquezna |
| Orexo US, INC. | $14.43 | 2023 | |
| Hologic Sales and Service, LLC | $14.11 | 2025 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.